Dr. Gary Steinberg on New AUA Guidelines for Bladder Cancer

Gary D. Steinberg, MD
Published: Monday, Jun 27, 2016



Gary D. Steinberg, MD, Bruce and Beth White family professor, professor of surgery, director, urologic oncology, University of Chicago Medicine, discusses new guidelines for for the management of non-muscle invasive bladder cancer (NMIBC) from the American Urological Association (AUA) and the Society of Urological Oncology (SUO).
 
The new guidelines were created from a compilation of all of the latest literature and the input of many experts in the field, says Steinberg. The guidelines include information concerning diagnosis, risk stratification, variant histologies, urine markers after diagnosis, intravesical therapy, BCG relapse and salvage regimens, TURBT/repeat resection, role of cystectomy, and risk adjusted surveillance and follow-up strategies.
 
The guidelines are succinct and straight-forward providing oncologists with a much better understanding as to how patients should  be managed and treated.
 


Gary D. Steinberg, MD, Bruce and Beth White family professor, professor of surgery, director, urologic oncology, University of Chicago Medicine, discusses new guidelines for for the management of non-muscle invasive bladder cancer (NMIBC) from the American Urological Association (AUA) and the Society of Urological Oncology (SUO).
 
The new guidelines were created from a compilation of all of the latest literature and the input of many experts in the field, says Steinberg. The guidelines include information concerning diagnosis, risk stratification, variant histologies, urine markers after diagnosis, intravesical therapy, BCG relapse and salvage regimens, TURBT/repeat resection, role of cystectomy, and risk adjusted surveillance and follow-up strategies.
 
The guidelines are succinct and straight-forward providing oncologists with a much better understanding as to how patients should  be managed and treated.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Moving Forward From the Status Quo for the Treatment of Soft Tissue Sarcoma: Key Questions & New Answers to Optimize OutcomesAug 16, 20181.5
Community Practice Connections™: Personalized Sequencing in Castration-Resistant Prostate Cancer: Bridging the Latest Evidence to the Bedside in Clinical ManagementAug 25, 20181.5
Publication Bottom Border
Border Publication
x